The Third Circuit is a prominent venue for pharmaceutical antitrust litigation. In this article, the authors provide an overview of the key developments in pharmaceutical antitrust cases coming out of the Third Circuit in the last year, focusing specifically on the Federal Trade Commission’s injunction request under section 13(b) of the FTC Act, indirect purchaser and competitor standing to sue under federal antitrust laws, class certification issues, and other antitrust allegations unique to the pharmaceutical industry.